Skip to main content

Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”

A Letter to the Editor to this article was published on 04 June 2022

The Original Article was published on 05 January 2021

This is a preview of subscription content, access via your institution.


  1. Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad Med J. 2014;90(1062):216–20.

    Article  PubMed  Google Scholar 

  2. Savage K, Flood K, Porter M, Kimball A. TNF-α inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2019;10:204062231985164.

    CAS  Article  Google Scholar 

  3. Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989–94.

    CAS  Article  PubMed  Google Scholar 

  4. Abdalla T, Lowes MA, Kaur N, Micheletti RG, Steinhart AH, Alavi A. Is there a role for therapeutic drug monitoring in patients with hidradenitis suppurativa on tumor necrosis factor-α inhibitors? Am J Clin Dermatol. 2021;22(2):139.

    Article  PubMed  Google Scholar 

  5. Chen W, Chi C. Association of hidradenitis suppurativa with inflammatory bowel disease. JAMA Dermatol. 2019;155(9):1022–7.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Giudici F, Maggi L, Santi R, et al. Perianal Crohn’s disease and hidradenitis suppurativa: a possible common immunological scenario. Clin Mol Allergy. 2015.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-106.

    Article  PubMed  Google Scholar 

  8. Plevris N, Jenkinson P, Arnott I, Jones G, Lees C. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn’s disease. Eur J Gastroenterol Hepatol. 2020;32(1):32–7.

    CAS  Article  PubMed  Google Scholar 

  9. Martorell A, Caballero A, González Lama Y, et al. Manejo del paciente con hidradenitis supurativa. Actas Dermosifiliogr. 2016;107:32–42.

    Article  PubMed  Google Scholar 

  10. Ghias M, Johnston A, Kutner A, Micheletti R, Hosgood H, Cohen S. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020;82(5):1094–101.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Mafalda Pestana.

Ethics declarations


The authors received no financial support for the authorship or publication of this article.

Conflict of interest

Mafalda Pestana, Margarida Brito Caldeira, and Joana Cabete have no conflicts of interest.

Author contributions

All authors contributed to the planning and design of the work. M.P. wrote the manuscript with input from all authors, who also read and agreed to the published version of the manuscript.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent to publish

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pestana, M., Brito Caldeira, M. & Cabete, J. Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”. Am J Clin Dermatol 23, 591–592 (2022).

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: